Literature DB >> 6191133

Cyclic GMP as possible mediator of coronary arterial relaxation by nicorandil (SG-75).

S Holzmann.   

Abstract

Since nicorandil (SG-75) is a potent vasodilator, has a terminal NO2 group, resembles nitroglycerin in its hemodynamic actions, which are likely to be mediated by cyclic GMP (cGMP), whether or not nicorandil relaxes vascular smooth muscle by a similar mechanism was investigated in isolated circular strips of bovine coronary arteries. It was found that nicorandil at concentrations producing dose-dependent relaxation up to 94% (0.47-473 microM) similar raised cGMP levels in the strips up to 10-fold of the control value, and that this effect preceded the mechanical response. When the breakdown of cGMP was blocked by a predominant inhibitor of cGMP phosphodiesterase, 2-o-propoxyphenyl-8-azapurin-6-one, both actions of nicorandil (cGMP increase and relaxation) were significantly potentiated. Inhibition of cGMP formation by methylene blue and, to a lesser extent, by ferricyanide, which antagonize guanylate cyclase activation by NO-yielding substances, significantly attenuated both actions of nicorandil under study. It was further demonstrated that nicorandil as well as nitroglycerin was a potent stimulator of soluble guanylate cyclase activity from bovine coronary arteries in vitro, an effect that was also susceptible to blockade by methylene blue or ferricyanide. These results indicate that nicorandil relaxes vascular smooth muscle, at least in part, through cGMP.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6191133     DOI: 10.1097/00005344-198305000-00004

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  37 in total

1.  Contribution of cyclic GMP formation to KRN2391-induced relaxation in coronary artery of the pig.

Authors:  Y Jinno; H Kasai; H Ohta; K Nishikori; H Fukushima; N Ogawa
Journal:  Br J Pharmacol       Date:  1992-08       Impact factor: 8.739

Review 2.  Potassium channel openers. Pharmacological effects and future uses.

Authors:  S Duty; A H Weston
Journal:  Drugs       Date:  1990-12       Impact factor: 9.546

Review 3.  Pharmacology of the potassium channel openers.

Authors:  G Edwards; A H Weston
Journal:  Cardiovasc Drugs Ther       Date:  1995-03       Impact factor: 3.727

4.  Proceedings of the British Pharmacological Society. 6th-8th January, 1988. Abstracts.

Authors: 
Journal:  Br J Pharmacol       Date:  1988-03       Impact factor: 8.739

Review 5.  Smooth muscle K+ channel openers; their pharmacology and clinical potential.

Authors:  A H Weston
Journal:  Pflugers Arch       Date:  1989       Impact factor: 3.657

6.  A double-blind comparison of nicorandil and metoprolol in stable effort angina pectoris.

Authors:  S Di Somma; V Liguori; M Petitto; A Carotenuto; D Bokor; O de Divitiis; M de Divitiis
Journal:  Cardiovasc Drugs Ther       Date:  1993-02       Impact factor: 3.727

7.  Protection by nicorandil against the dysfunction of the central vagal baroreflex system following transient global cerebral ischaemia in dogs.

Authors:  J Kurihara; N Ochiai; H Kato
Journal:  Br J Pharmacol       Date:  1993-08       Impact factor: 8.739

8.  Controlled comparison of the pharmacodynamic effects of nicorandil (SG-75) and isosorbide dinitrate in man.

Authors:  G G Belz; J Matthews; J Heinrich; G Wagner
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

9.  Effect of nicorandil on abnormal coronary flow reserve assessed by exercise 201Tl scintigraphy in patients with angina pectoris and nearly normal coronary arteriograms.

Authors:  H Yamabe; H Namura; T Yano; H Fujita; S Kim; M Iwahashi; K Maeda; M Yokoyama
Journal:  Cardiovasc Drugs Ther       Date:  1995-12       Impact factor: 3.727

10.  Effects of nicorandil on cell proliferation and cholesteryl ester accumulation in arterial smooth muscle cells in culture.

Authors:  R Fujiwara; T Hayashi; Y Kutsumi; K Oida; T Tamai; T Nakai; S Miyabo
Journal:  Cardiovasc Drugs Ther       Date:  1993-06       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.